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Abstract
Background: Ovarian cancer is one of the most lethal types of female malignancy. Although most patients are initially
responsive to platinum-based chemotherapy, almost all develop recurrent chemoresistant tumors and succumb to their
diseases. Elucidating the pathogenesis underlying drug resistance is fundamental to the development of new therapeutics,
leading to improved clinical outcomes in these patients.
Methods and Findings: We compared the proteomes of paired primary and recurrent post-chemotherapy ovarian high-
grade serous carcinomas from nine ovarian cancer patients using CIEF/Nano-RPLC coupled with ESI-Tandem MS. As
compared to their primary tumors, more than half of the recurrent tumors expressed higher levels of several proteins
including CP, FN1, SYK, CD97, AIF1, WNK1, SERPINA3, APOD, URP2, STAT5B and RELA (NF-kB p65), which were also validated
by quantitative RT-PCR. Based on shRNA screening for the upregulated genes in in vitro carboplatin-resistant cells, we found
that simultaneous knockdown of RELA and STAT5B was most effective in sensitizing tumor cells for carboplatin treatment.
Similarly, the NF-kB inhibitor, BMS-345541, and the STAT5 inhibitor, Dasatinib, significantly enhanced cell sensitivity to
carboplatin. Moreover, both RELA and STAT5 are known to bind to the promoter region of Bcl-X, regulating its promoter
activity. In this regard, augmented Bcl-xL expression was detected in carboplatin-resistant cells. Combined ectopic
expression of RELA and STAT5B enhanced Bcl-xL promoter activity while treatment with BMS-345541 and Dasatinib
decreased it. Chromatin immunoprecipitation of the Bcl-X promoter region using a STAT5 antibody showed induction of
RELA and STAT5 DNA-binding segments both in naı ¨ve cells treated with a high concentration of carboplatin as well as in
carboplatin-resistant cells.
Conclusions: Proteomic analysis identified RELA and STAT5 as two major proteins associated with carboplatin resistance in
ovarian tumors. Our results further showed that NF-kB and STAT5 inhibitor could sensitize carboplatin-resistant cells and
suggest that such inhibitors can be used to benefit patients with carboplatin-resistant recurrent ovarian cancer.
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Introduction
Ovarian cancer is the most lethal gynecological malignancy in
the United States with an estimated 21,550 new cases and 14,600
deaths in 2009 [1]. Among all histological types of ovarian
epithelial carcinoma, high-grade serous carcinoma is the most
common and aggressive type, and is referred to generally as
‘‘ovarian cancer’’. High-grade serous carcinoma is highly
malignant with a 5-year survival rate of less than 30%. The
majority of patients are diagnosed late after tumor cells have
disseminated within the peritoneal cavity when surgical and
medical intervention is far less effective. Patients with advanced
stage disease are treated with cytoreduction surgery followed by
carboplatin-based chemotherapy. Despite initial responsiveness to
combined carboplatin and paclitaxel chemotherapy, most patients
develop chemoresistant tumors and ultimately succumb to the
recurrent disease [2]. Thus, elucidating the pathogenesis of
chemoresistance is fundamental to the development of new
therapeutics to overcome drug resistance in ovarian cancer
patients.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11198To elucidate the molecular mechanisms of drug resistance
investigators have employed several genome-wide techniques,
including transcriptome analysis, to identify genes and their
associated pathways in developing chemoresistance. As a result, a
number of new drug resistant-associated genes have been
identified. For example, we have reported that the expression
levels of Nac1, Rsf-1 (HBXAP), fatty acid synthase and annexin
A11 were significantly higher in recurrent, high-grade ovarian
serous carcinoma specimens after chemotherapy and, more
importantly, expression of these genes played a causal role in
conferring drug resistance in vitro [3], [4], [5], [6], [7], [8]. In
addition to genomic approaches, comparison of the proteomes
between primary and recurrent post-chemotherapeutic carcino-
mas could represent another effective approach to identifying
proteins involved in developing drug resistance. Proteins are the
ultimate functional products of genetic information, and the
application of proteomics approaches such as 2D difference gel
electrophoresis, MALDI imaging mass spectrometry, electron
transfer dissociation mass spectrometry and reverse-phase protein
array analysis has identified novel disease-related proteins in
cancer [9], [10].
In our effort to elucidate the pathogenesis of drug resistance in
ovarian cancer, we have employed oncoproteomics as a discovery
tool to identify the proteins preferentially expressed in recurrent
post-chemotherapy ovarian carcinoma tissues using capillary
isoelectric focusing (CIEF) coupled with nano-reversed-phase
liquid chromatography (RPLC) for concentrating and resolving
intact proteins. This approach has been shown to enhance the
capacity to analyze complex protein mixtures from a limited
amount of a specimen [11]. Candidate proteins were screened for
their contribution to carboplatin resistance using shRNAs and in
vitro chemoresistant cell models. In the results reported here, we
show that RELA (p65 subunit of NF-kB) and STAT5 are the
major proteins associated with carboplatin resistance in ovarian
cancer, and show that they both bind the promoter and act
synergistically to induce the expression of Bcl-xL, the molecular
convergence point of the NF-kB and STAT5 pathways. Co-
inhibition of these two pathways by RNAi or small compound
inhibitors represents an attractive strategy for a combined




Acquisition of tissue specimens and clinical information were
approved by an institutional review board (Johns Hopkins Medical
Institutions) and by the Regional Ethics Committee (Norwegian
Radium Hospital). The written informed consents were obtained
from all patients.
Clinical Samples and Cell lines
Ovarian cancer effusion samples were obtained from the
Norwegian Radium Hospital. These included 9 pairs of matched
primary and recurrent high-grade ovarian serous carcinoma
ascites cell pellets (Table S1). Human cancer cell lines including
293T, OVCAR3, SKOV3, and A2780 cells were originally
purchased from ATCC (Rockville, MD) and were cultured in
RPMI1640 medium supplemented with 5% fetal bovine serum.
To generate in vitro chemoresistant ovarian cancer cells, SKOV3,
A2780, and OVCAR3 cells were selected by sustained treatment
with different concentrations of carboplatin ranging from 0.2 mg/
ml–4.0 mg/ml. Resistant colonies of each cell line were pooled and
used for subsequent experiments. Chemoresistant cell lines were
maintained in selective medium containing the highest tolerable
concentrations of carboplatin (2.0 mg/ml for SKOV3-CR, 1.0 mg/ml
for A2780-CR, and 0.5 mg/ml for OVCAR3-CR) [6]. Figures S1 A
and S1 B show drug sensitivity assays (carboplatin IC50) and growth
curve analysis of A2780-CR, SKOV3-CR and OVCAR3-CR as
compared to their naı ¨ve counterparts.
Proteomics analysis
Proteins extracted from clinical samples were analyzed using
integrated Capillary Isoelectric Focusing (CIEF)/Nano-Reversed
Phase Liquid Chromatography (Nano-RPLC) Separations Cou-
pled with ESI-Tandem MS (Electrospray Ionization -Tandem
Mass Spectrometry). The Open Mass Spectrometry Search
Algorithm (OMSSA) developed at the National Center for
Biotechnology Information was used to search the peak list files
against a decoyed SwissProt human database. A total of 6,711
proteins were identified at a 1% false discovery rate (FDR) as
determined by the target-decoy search method (see supplemental
materials: Text S1, Figures S2 and S3 for detailed explanation).
The 24 candidate proteins with high peptide counts and low
paired t-test p-values that exhibited more than 2-fold upregulation
in at least 4 out of 9 recurrent cases compared to their primaries
were selected for subsequent validation by quantitative RT-PCR.
The expression data of all proteins identified in this study are
shown in Table S2.
Drug sensitivity and cell viability assays
The shRNA plasmids targeting candidate genes and the control
plasmid (pLKO.1-puro vector only) were obtained from Sigma.
The shRNA nucleotide sequences are listed in Table S3.
Transfection was performed using the Fugene HD (Roche)
(293T, A2780, SKOV3-CR, A2780-CR), and the Nucleofection
kit V (program V-05 for SKOV3) (Amaxa Biosystems). For each
gene, shRNAs that showed the best knockdown effect among the 4
or 5 shRNAs screened were subsequently selected for drug
sensitivity experiments. Table S4 shows the knockdown efficiency
of all shRNAs in SKOV3-CR cells using qRT-PCR. For drug
sensitivity assays, cells were transfected with targeting and control
shRNAs, selected with Puromycin for 5–7 days, and then seeded
into 384-well plates at a density of 750 cells/well. After overnight
culture, the cells were treated with a series of concentrations of
carboplatin and/or BMS-345541 (Cat.401480, Calbiochem),
and/or Dasatinib (D-3307, LC Laboratories). Four days after
transfection (i.e., three days after drug treatment), viable cells were
counted by CellTiter-Blue
TM (Promega) using a fluorescence
microplate reader (Fluostar from BMG, Durham, NC). Data were
determined from three replicates and are expressed as the
percentage of control group without carboplatin treatment.
Quantitative real-time reverse transcription-PCR
An RNA extraction kit (Qiagen) was used to extract total RNA,
and the Superscript II First-strand cDNA synthesis kit (Invitrogen)
was used to generate cDNA. Real-time PCR was performed on a
Bio-Rad iCyclers (MyIQ, IQ4), and data analysis was performed
using the Bio-Rad IQ5 v2 software. The PCR primers used in this
study are listed in Table S5. The mean Ct of the gene of interest
was calculated from replicate measurements and normalized with
the mean Ct of a control gene, GAPDH, for which expression was
relatively constant.
Western blot
Western blot analysis was conducted using a standard protocol.
Mouse monoclonal antibodies that react to Stat5b (G-2) (sc-1656,
RELA, STAT5 in Chemoresistance
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RELA (NF-kB p65) (MAB3026, Millipore) were used at a 1:400
dilution, and a rabbit anti-GAPDH polyclonal antibody (Sigma,
Cat # G9545) was used at a 1:4,000 dilution. Similar amounts of
total protein from each lysate were loaded and separated on 4–
12% Tris-Glycine-SDS polyacrylamide gels (Novex, San Diego,
CA) and electroblotted to Millipore Immobilon-P polyvinylidene
difluoride membranes. Western blots were developed by chemi-
luminescence (Pierce, Rockford, IL).
Apoptosis assay
Cells were treated with DMSO, and/or carboplatin (6 mg/ml),
and/or BMS-345541 (5 mM), and/or Dasatinib (100 nM) for
48 hours, and then analyzed using an Annexin V-FITC apoptosis
detection kit (BioVision) according to the manufacturer’s protocol.
The apoptotic population (Annexin V-positive) was measured by
Flow Cytometry (Ex=488 nm; Em=530 nm) using FITC signal
detector (FL1), and the phycoerythrin emission signal detector
(FL2) for PI-positive cells.
Luciferase reporter assay and CAT ELISA assay
For luciferase assay, cells were transfected with the pGL2 firefly
reporter vector (Promega) or with either pGL2-Stat5-wt or pGL2-
Stat5-mut containing a 1.0 kb Bcl-X promoter without or with,
respectively, a point mutation in the Stat5 consensus binding
sequence (C/T) (a generous gift from Dr Fabrice Gouilleux) [12].
Human pCMV-RELA and pCMV-HA were kind gifts from Dr.
Paul J Chiao [13] and pCMV-STAT5B was a kind gift from Dr.
Amy H. Bouton [14]. pRL-Renilla reporter vector (Promega),
which serves to monitor transfection efficiency, was co-transfected
with the pGL2 plasmid. Luciferase activity was determined
using Dual-Glo luciferase reagent (Promega). Firefly luciferase
activity was normalized to luminescence from Renilla luciferase
and the ratio of luminescence from the experimental reporter
to luminescence from the control reporter was calculated. For
CAT assay, cells were co-transfected with pRL-Renilla and
various CAT reporter constructs in pCAT-Basic (Promega).
These were: 2298/+22 wt, 2298/+22kb mut, 2207/+22, and
2137/+22, which were a generous gift from Dr. Celine Gelinas
[15]. The 2298/+22kb mut construct has three point muta-
tions in the NF-kB p65 consensus binding site in the Bcl-X
promoter (GGG/TTT). Forty-eight hours after transfection, CAT
assays were performed using a CAT ELISA assay kit (Roche)
and Renilla luminescence served as a transfection efficiency
control.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation (ChIP) was performed using
the ChIP-IT enzymatic kit (Active motif) on untreated carboplat-
in-resistant cells and their naı ¨ve counterparts, as well as on naı ¨ve
cells treated with carboplatin (12 mg/ml) for 24 h prior to fixation
with 1% paraformaldehyde. The lysates of fixed cells were treated
with an enzymatic shearing cocktail (Active Motif, Carlsbad, CA)
and the soluble fraction was incubated with 4 mL of anti-Stat5 (C-
17) (sc-835X, Santa Cruz Biotechnology) or normal rabbit IgG,
and precipitated with protein-G magnetic beads at 4uC overnight.
To reverse crosslinking immunoprecipitated DNA was heated at
65uC for 6 hours, followed by proteinase K (10 mg/ml) treatment.
The detection primers for the Bcl-X promoter included 2824 bp
to 2588 bp (59 side of RELA and STAT5 binding site), 2412 bp
to 2330 bp (contains RELA and STAT5 sites), and 2283 bp to
2117 bp (39 side). Quantitative PCR was performed using the
SYBR Green-based detection system as described above with PCR
primers that amplified different Bcl-X promoter regions (primer
sequences are shown in Table S5). Input DNA was defined as an
aliquot of sheared chromatin prior to immunoprecipitation, and
was used to normalize the amount of chromatin used in each
experiment.
Results
Identification and validation of candidate proteins in
recurrent ovarian serous carcinoma
The cell pellets from 18 ascites samples including the paired
primary and recurrent post-chemotherapy ovarian high-grade
serous carcinomas (Table S1) were analyzed using capillary
isoelectric focusing/nano-reversed phase liquid chromatography
coupled with ESI-tandem MS. Levels of 24 proteins were more
than 2 fold higher in recurrent tumor cells compared to matched
primary tumor cells from the same patient in at least 4 pairs of
samples (Figure 1A). Candidate proteins upregulated in
recurrent tumors included cell adhesion proteins, cell-extracel-
lular matrix interaction proteins, cell surface glycoproteins (FN1,
STIM1, CD97), protein kinases (SYK, WNK1), acute phase
proteins (SERPINA3, CTSS), proteins induced by pro-inflam-
matory cytokines, interferon and growth factors (AIF1, RELA,
IL18, STAT5A, STAT5B). The expression of the 24 candidate
proteins was validated using quantitative RT-PCR in the
same set of clinical samples, as well as in the three pairs of
carboplatin-naı ¨ve and resistant (CR) ovarian cancer cell lines
(Figure 1B and 1C). We found that the majority of the 24
candidate genes had higher mRNA expression levels in
recurrent tumors than in primary tumors (Figure 1B), and that
the carboplatin-resistant cells also had higher mRNA levels than
naı ¨ve cells (Figure 1C).
Identification of RELA and STAT5B as the major
carboplatin-resistant proteins in recurrent ovarian serous
carcinoma
In order to prioritize the recurrent tumor-associated candidate
proteins for assessment of their roles in chemoresistance in vitro,w e
selected 11 genes validated by RT-PCR including CP, STAT5B,
FN1, CD97, RELA (NF-kB p65), AIF1, SYK, WNK1, URP2,
SERPINA3 and APOD because they were upregulated in at least
2 out of 3 pairs of carboplatin-resistant cells. We used shRNAs to
knockdown their expression in SKOV3-CR cells. Growth curve
analyses were carried out to determine whether shRNA knock-
down of the candidate genes had an effect on cell proliferation in
the absence or presence of carboplatin (see Figure S4 for all
screening results). Among the 11 genes, suppression of STAT5B,
RELA, CD97,and WNK1 had a minimal effect on cell proliferation
(Figure 2A), but significantly sensitized chemoresistant cells to
carboplatin (Figure 2B). The IC50 of STAT5B, CD97, RELA, and
WNK1 were 12.5 mM, 17.8 mM, 19.8 mM, and 27.3 mM,
respectively, compared to 44.2 mM by the control shRNA.
Because drug resistance is likely to involve several genes and
pathways, we simultaneously knocked down the expression of two
of these genes, and found that combined suppression of STAT5B
and RELA was most effective, as the IC50 decreased to 7.3 mMa s
compared to 26.6 mM by control shRNA under this experimental
condition (Figure 2C). Figure 2D shows the protein knockdown
effect by the specific shRNAs in both SKOV3-CR and A2780-CR
cell lines. Moreover, Western blot using specific antibodies against
activated RELA and STAT5B demonstrated higher protein
expression levels in SKOV3-CR cells and to a lesser extent in
A2780-CR cells prior to knockdown as compared to their naı ¨ve
counterparts (Figure 2E).
RELA, STAT5 in Chemoresistance
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upregulated Bcl-xL transcription
RELA and STAT5 proteins have specific binding sites on the
Bcl-X promoter, and regulate one of the two Bcl-X isoforms, Bcl-
xL, which is an anti-apoptotic protein involved in maintaining
cell survival under stresses such as genotoxic drugs. Thus, it is
likely that RELA and STAT5 proteins cooperate in inducing
Bcl-X promoter activity and synergistically enhance Bcl-xL
expression in chemoresistant ovarian cancer cells. To test this
hypothesis, we performed reporter assays and chromatin
immunoprecipitation in 293T and ovarian cancer cell lines.
Figure 3A illustrates the five reporter constructs used in the
analyses. Specifically, the STAT5-mut harbored a point
mutation in the STAT5 consensus binding site, while the
2298/22kB mut had three base substitutions in the RELA/p50
consensus binding site. In Figure 3B, the Bcl-X promoter assay
using STAT5 wt and STAT5 mut constructs showed the highest
reporter activity in 293T cells after introducing exogenous
expression of both RELA and STAT5B. Interestingly, although
the point mutation in STAT5 binding site was shown to
completely eliminate binding activity in Ba/F3 murine pro-B
cells [12], it revealed only a subtle decrease in the Bcl-X
promoter activity as shown here. We next investigated regulation
of the Bcl-X promoter by endogenous RELA and STAT5
expression in SKOV3-CR, A2780-CR and their naı ¨ve counter-
parts. Cells treated with a combination of 5 mM BMS-345541, a
highly-selective IkB kinase inhibitor [16], and 100 nM dasatinib,
a protein-tyrosine kinase inhibitor that inhibits STAT5 signaling
[17], demonstrated the lowest Bcl-X reporter activity of STAT5
wt and STAT5 mut constructs, followed by BMS-345541 alone,
dasatinib alone, and DMSO alone (Figure 3C). Both carboplat-
in-resistant cells exhibited higher Bcl-X promoter activity than
their naı ¨ve counterparts. Reduced Bcl-xL expression levels after
treatment with 5 mM BMS-345541 or 100 nM dasatinib for
24 hours were also confirmed in both SKOV3-CR and A2780-
CR cells (data not shown). As shown in Figure 3D, cells
Figure 1. Identification and validation of candidate proteins in recurrent ovarian serous carcinoma. A) Proteomics analysis showing the
expression ratio of recurrent to primary tumor in 24 candidate proteins. Nine pairs of matched primary and recurrent serous carcinomas (from #1t o
#9) were analyzed and the pseudo-color codes represent the fold change (ratio of recurrent to primary tumor) from low (blue) to high (red). B) mRNA
expression of candidate genes in recurrent and primary tumors using the same 9 pairs of samples utilized in proteomics analysis. Color codes
represent the relative expression levels from low (blue) to high (red). C) mRNA expression of candidate genes in chemoresistant ovarian cancer cells;
CR = Carboplatin Resistant. Color codes represent the relative expression levels from low (blue) to high (red).
doi:10.1371/journal.pone.0011198.g001
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wild-type binding sites of RELA/p50 and STAT5, had the
highest reporter activity, followed by 2298/22kBm u ta n d
2207/+22 constructs, which contained only one intact STAT5
binding site. The 2137/+22 construct, depleted of both binding
sites, showed the lowest activity. These observations indicated
that carboplatin-resistant cells had higher Bcl-X reporter activity
than their naı ¨ve counterparts.
We performed chromatin immunoprecipitation (ChIP) analysis
using an antibody against STAT5 and quantified the pulled down
chromatin fragments using quantitative PCR. We used untreated
SKOV3-CR, A2780-CR, and their naı ¨ve counterparts, as well as
naı ¨ve cells treated with a high dose carboplatin (12 mg/ml) as a
positive control. The results in Figures 4A and 4B show that in a
resting state, chemoresistant cells exhibited a subtle increase in
STAT5-DNA binding to the Bcl-X promoter as compared to
naı ¨ve cells, while naı ¨ve cells acutely treated with high dose
carboplatin had the highest STAT5-DNA binding. Taken
together, these results strongly suggest that RELA and STAT5
co-regulated Bcl-X promoter in response to carboplatin, and
conferred chemoresistance in ovarian cancer, in part, through the
transcriptional activation of Bcl-xL.
Bcl-xL expression is enhanced in chemoresistant cells and
its suppression reduces carboplatin resistance
To determine the anti-apoptotic effect of Bcl-xL upon
carboplatin treatment, we first compared Bcl-xL gene expression
levels in the three pairs of ovarian chemoresistant-naı ¨ve cell lines
by quantitative RT-PCR and confirmed that Bcl-xL expression
levels were higher in the chemoresistant cells as compared to their
corresponding naı ¨ve cells, especially in A2780-CR (Figure 5A).
Next, we knocked down Bcl-xL expression in SKOV3-CR and
A2780-CR cells using the Bcl-xL-specific shRNA and determined
their carboplatin IC50. As expected, reduced Bcl-xL expression
resulted in moderate carboplatin sensitization in both cell lines
(IC50=88.80 mM for shRNA control, 70.70 mM for Bcl-X shRNA
(SKOV3-CR); 91.36 mM for shRNA control, 58.00 mM for Bcl-X
shRNA (A2780-CR)) (Figures 5B and 5C).
Co-inhibition of RELA and STAT5B expression by small
molecule inhibitors synergistically sensitizes
chemoresistant ovarian cancer cells to carboplatin
To extend the above findings that specific shRNAs against
RELA and STAT5B effectively sensitized chemoresistant ovarian
Figure 2. Identification of RELA and STAT5B as the major carboplatin-resistant genes in recurrent ovarian serous carcinoma. A)
SKOV3 carboplatin-resistant cells (SKOV3-CR) were transfected with candidate gene-specific shRNAs, and cell growth was monitored for 6 days. B)
SKOV3-CR cells were transfected with specific shRNAs against each candidate gene (STAT5B, WNK1, RELA, CD97), and selected with puromycin for 5–
7 days. The cells were then treated with various concentrations of carboplatin for 4 days, and the IC50 was determined for each gene by cell viability
assay. C) SKOV3-CR cells were co-transfected with combinations of two shRNAs against STAT5B, WNK1, RELA, CD97, and selected with puromycin for
5–7 days. The cells were then treated with various concentrations of carboplatin for 4 days, and IC50 was determined for each gene by cell viability
assay. D) Western blots showing reduced RELA and STAT5B expression 48 hours after transfection of their specific shRNAs in SKOV3-CR and A2780-CR
cells. E) Western blots showing endogenous expression level of RELA and STAT5B in A2780 naı ¨ve, A2780-CR, SKOV3 naı ¨ve, and SKOV3-CR cells.
doi:10.1371/journal.pone.0011198.g002
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effect of their small molecule inhibitors as potential chemosensi-
tizers. SKOV3-CR and A2780-CR cells were cultured with
various concentrations of carboplatin in combination with
BMS-345541, a specific NF-kB signaling inhibitor. BMS-345541
markedly enhanced carboplatin-induced growth suppression
(carboplatin IC50=6.27 mM for SKOV3-CR and 9.62 mM for
A2780-CR) as compared to cells treated with BMS-345541 only
(IC50=118.06 mM for SKOV3-CR and 181 mM for A2780-CR),
and carboplatin only (IC50=247.61 mM for SKOV3-CR and
74.84 mM for A2780-CR) (Figure 6A). To determine if the
STAT5 inhibitor, dasatinib (BMS-324825), could collaborate
with BMS-345541 in sensitizing cell to growth inhibition by
carboplatin, we treated the two carboplatin ovarian cancer cell
lines with various concentrations of carboplatin and dasatinib
and with a fixed concentration of BMS-345541 (5 mM, BMS-
345541 IC50). IC50 analysis showed that chemoresistant cells
treated with the combination of carboplatin, dasatinib, and 5 mM
BMS-345541 exhibited the highest sensitization to carboplatin
killing (IC50=7.03mM for SKOV3-CR; 41.14 mM for A2780-
CR), followed by those treated with dasatinib and carboplatin
(IC50=74.84 mM for SKOV3-CR; 56.30 mM for A2780-CR),
and carboplatin alone (IC50=125.00mM for SKOV3-CR;
64.90 mM for A2780-CR) (Figure 6B). Of note, the growth of
cells treated with various doses of dasatinib alone was not
significantly reduced even at a concentration as high as
1000 nM.
As the chemosensitizing effects of dasatinib can be related to its
ability to suppress several signaling pathways in addition to
STAT5, we replaced dasatinib with STAT5B-specific shRNA in
the IC50 assays to confirm that the effect of dasatinib observed was
a result of STAT5 inhibition. We found that similar to dasatinib,
STAT5B-specific shRNA synergized with BMS-345541 in con-
ferring the best chemosensitization effect, again indicating that co-
inhibition of STAT5 and NF-kB is a promising strategy for the
treatment of carboplatin-resistant ovarian cancers (Figure 6C). To
Figure 3. Co-induction of RELA and STAT5 in chemoresistant cells results in upregulated Bcl-xL transcription. A) Schematic illustration
of the six Bcl-X reporter constructs used in this study. The name of CAT constructs reflects their length relative to the first nucleotide in the Bcl-xL
cDNA. STAT5-mut contains a point mutation in the Stat5 consensus binding site, while -298/22kB mut has three base substitutions in the RELA/p50
consensus binding site. B) Bcl-X promoter assay using 293T cells transfected with STAT5-wt or STAT5-mut or control reporter plasmid, plus pCMV-
RELA and/or pCMV-STAT5B. Luciferase activity was measured 24 hours after transfection (right panel); exogenous RELA and STAT5B expression level
at 24 hours after transfection of pCMV-RELA or pCMV-STAT5B or control plasmid (left panel). C) Bcl-X reporter assay in chemoresistant cells and their
naı ¨ve counterparts transfected with STAT5-wt or STAT5-mut or control reporter plasmid (top panel: SKOV3; bottom panel: A2780). Luciferase activity
was measured 24 hours after treatment with 5 mM BMS-345541 and/or 100 nM dasatinib and/or DMSO. D) CAT ELISA assay of chemoresistant cells
and their naı ¨ve counterparts. CAT activity was measured 48 hours after transfection with the CAT-reporter plasmids (top panel: SKOV3; bottom panel:
A2780)
doi:10.1371/journal.pone.0011198.g003
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carboplatin-sensitization effect via induction of carboplatin-
induced apoptosis, we performed annexin V staining on
chemoresistant cells and their naı ¨ve counterparts treated with
5 mM BMS-345541 and/or 100 nM dasatinib in combination
with 6 mg/ml carboplatin. As shown in Figure 6D, cells treated
with the combination of carboplatin plus low doses of BMS-
345541 and dasatinib showed the highest percentage of annexin
V-positive cells. Both SKOV3-CR and A2780-CR, and to a
lesser extent their naı ¨ve counterparts, exhibited enhanced
carboplatin-induced apoptosis when co-treated with BMS-
345541 or dasatinib. In agreement with the earlier results,
chemoresistant cells expressed higher amounts of RELA and
STAT5B proteins than did the naı ¨ve cells, and may be more
dependent on these pathways for cell survival, thereby
becoming more sensitive to the inhibitors. It is also interesting
to note that among the two chemoresistant cells used in our
study, A2780-CR had a smaller induction of RELA and
STAT5B expression in relation to its naı ¨ve counterpart as
compared to SKOV3-CR (Figure 2E). Consistently, although
A2780-CR was more sensitive to carboplatin treatment than
SKOV3-CR, its response to the growth inhibitory effect of
NF-kB and STAT5 inhibitors was to a lesser extent. This
observation supports the notion that drug resistance is a
complex phenotype and suggests that other molecular mecha-
nisms may also participate in the development of carboplatin
resistance in A2780-CR cells.
Discussion
In this study, we used proteomic analysis and functional
screening to identify RELA and STAT5B as the two major
proteins involved in carboplatin resistance in ovarian cancer. We
demonstrated that both proteins bound to the Bcl-X promoter and
enhanced the expression of Bcl-xL which has been known to play a
causal role in conferring carboplatin resistance in ovarian cancer
through its anti-apoptotic functions [18]. Inhibition of either
expression or activity of RELA and STAT5B decreased Bcl-xL
expression levels and increased carboplatin sensitivity in carbo-
platin-resistant ovarian cancer cells. Our results provide new
insight into the molecular processes underlying the development of
carboplatin resistance in ovarian cancer and have important
clinical implication.
The majority of the candidate proteins upregulated in recurrent
tumors were proteins such as SERPINA3, AIF1, IL18, RELA,
STAT5A and STAT5B that are either expressed in response to
stimulation by pro-inflammatory cytokines or are involved in
inflammatory networks. This observation is consistent with recent
reports demonstrating that pro-inflammatory cytokines and
inflammatory response pathways play an important role in
ovarian cancer progression and chemoresistance [19], [20]. More
specifically, Konstantinopoulos et al. have reported that NRF2,
NF-kB, cytokines and proteins involved in inflammatory response
pathways are highly induced by carboplatin treatment [19].
Similarly, one of the major findings in our study was the
Figure 4. Chromatin immunoprecipitation (ChIP) assay of the Bcl-X promoter using STAT5 antibody in chemoresistant cells, their
naı ¨ve counterparts, and naı ¨ve cells treated with high-dose carboplatin. A) Relative fold enrichment of immunoprecipitated genomic
fragments by quantitative PCR in chemoresistant cells and in naı ¨ve cells treated with 12 mg/ml carboplatin for 24 hours, as compared to the
untreated naive counterparts. Fragment ‘‘2412 bp,2330 bp’’ contains both RELA and STAT5 binding sites, while fragment ‘‘2824 bp,2588 bp’’
on the 59 side of RELA and STAT5 binding sites and fragment ‘‘2283 bp,2117 bp’’ on the 39 side serve as negative controls. Top panel: SKOV3;
bottom panel: A2780. B) STAT5-bound chromatin in relation to % of total chromatin input of the ‘‘2412 bp,2330 bp’’ region. Rabbit IgG-bound
chromatin serves as control. Top panel: SKOV3; bottom panel: A2780.
doi:10.1371/journal.pone.0011198.g004
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therapy ovarian cancer cells. RELA (NF-kB p65) is one of the
three transcriptional activator units of NF-kB along with RELB
and c-REL. The above findings raise the possibility that recurrent
tumors are enriched by cells exhibiting a cancer stem cell-like
phenotype. Ovarian cancer stem cell-like cells have been reported
to exhibit the capacity to promote a pro-inflammatory microen-
vironment by constitutive NF-kB activity and cytokine and
chemokine production. They are also proficient in DNA repair
and are resistant to conventional chemotherapeutic agents [20].
Hence, in line with our findings, pro-inflammatory and cytokine
regulatory proteins are likely major players in ovarian cancer
chemoresistance either via the direct growth-promoting/anti-
apoptotic effect or via the creation of growth-supportive niches/
microenvironment for ovarian cancer stem cell-like cells.
Normally, the subcellular location of NF-kB is controlled by its
binding to a family of inhibitory proteins, IkBs, which mask its
nuclear localization signal, thus preventing nuclear localization.
Phosphorylation of IkBb yI kB kinase (IKK) leads to its
ubiquitination and subsequent NF-kB translocation to the nucleus
[21]. NF-kB is involved in the vast majority of stress-induced,
immune, and inflammatory responses. It is also an important
regulator in cell fate decisions, such as programmed cell death and
proliferation control, and is critical in tumorigenesis. Its role in the
development of chemoresistance in ovarian cancer has previously
been reported [22], [23].
STAT5 isoforms including STAT5A and STAT5B mainly
share a similar molecular structure and function. STAT5 has been
demonstrated to be an essential molecule in the pathogenesis of
leukemia [24] and solid tumors including liver cancer, lymphoma,
head and neck cancer, and prostate cancer [25], [26], [27], [28].
Although our proteomics screening identified both STAT5A and
STAT5B as upregulated proteins in recurrent ovarian cancer, we
focused on studying STAT5B in our shRNA screens because it
Figure 5. The expression level of Bcl-xL is increased in chemoresistant cells and its suppression reduces carboplatin resistance. A)
mRNA expression of Bcl-xL in carboplatin-resistant and naı ¨ve ovarian cancer cells based on qRT-PCR. B and C) Knockdown effect of Bcl-xL shRNA in
SKOV3-CR cells (B) and in A2780-CR cells (C). After transfection with Bcl-xL shRNA and selection with puromycin for 5–7 days, Bcl-xL expression level
decreases (left panels). The cells were then treated with carboplatin at various concentrations for 4 days. IC50 curves were determined using cell
viability assay (right panels).
doi:10.1371/journal.pone.0011198.g005
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Interestingly, reduced STAT5B did not show growth suppression
in chemoresistant cells, instead it sensitized the cells to carboplatin,
suggesting a role in regulation of chemotherapy-induced apoptosis
in ovarian cancer rather than direct participation in cellular
proliferation.
In this study, we further demonstrated that, as compared to
naı ¨ve cells, chemoresistant ovarian cancer cells showed increased
levels of RELA and STAT5 binding to the Bcl-X promoter. The
binding of both nuclear proteins to the Bcl-X promoter resulted in
enhanced transcriptional activation of Bcl-xL. Moreover, we
showed that co-inhibition of NF-kB and STAT5 pathways, either
by specific shRNAs or small molecule inhibitors, synergistically
reduced the chemoresistance potential in carboplatin-resistant
ovarian cancer cells partly through suppression of Bcl-xL
expression. Bcl-xL is known to be involved in ovarian cancer
chemoresistance [29], [30], and the current study provides further
evidence that Bcl-xL expression is significantly enhanced in
carboplatin-resistant ovarian cancer cells. Bcl-X encodes two
apoptosis regulators with opposing effects; Bcl-xL, a long form,
exerts anti-apoptotic activity, while Bcl-xS, a short form, exerts
proapoptotic activity. Although Bcl-xL and Bcl-xS share the same
promoter, RELA/p50 [13], [15] and STAT5 [12], [31] have been
shown to selectively induce the production of Bcl-xL in lymphoid
Figure 6. Co-inhibition of RELA and STAT5B pathways by small molecule inhibitors synergistically sensitizes chemoresistant
ovarian cancer cells to cytotoxic effect of carboplatin. A) SKOV3-CR (left panel) and A2780-CR cells (right panel) were treated with a series of
concentrations of carboplatin and BMS-345541 for 4 days before IC50 curves were obtained. B) SKOV3-CR (left panel) and A2780-CR cells (right panel)
were treated with a series of dasatinib concentrations, or a series of carboplatin concentrations, or 5 mM BMS-345541 in combination with a series of
dasatinib concentrations, or a series of concentrations of dasatinib and carboplatin, or 5 mM BMS-345541 in combination with a series of
concentrations of dasatinib and carboplatin for 4 days before IC50 curves were measured. C) SKOV3-CR (left panel) and A2780-CR cells (right panel)
were either transfected with STAT5B- or control shRNAs, with or without 5 mM BMS-345541 treatment, and subjected to a series of concentrations of
carboplatin for 4 days before IC50 curves were determined. D) Annexin V assay to measure apoptosis of chemoresistant cells and their naı ¨ve
counterparts after treatment with carboplatin (6 mg/ml) and/or BMS-345541 (5 mM) and/or dasatinib (100 nM) for 48 hours. Annexin V positive cells
were quantified using flow cytometry. Left panel: SKOV3-CR; right panel: A2780-CR.
doi:10.1371/journal.pone.0011198.g006
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chemoresistant ovarian cancer cells show increased RELA and
STAT5-dependent transcriptional activation and protein-DNA
binding at the Bcl-X promoter, supporting the view that
carboplatin resistance in ovarian cancer cells is at least in part
mediated by the NF-kB/STAT5-Bcl-xL axis.
Targeted therapy has shown promise in improving the clinical
outcome in certain types of human cancer and it has been
proposed that targeted strategies may be useful for enhancing the
effects of chemotherapeutics. To this end, several small molecule
inhibitors of the NF-kB pathway such as RTA-402 and
Bortezomib, have been evaluated in clinical trials [32]. In the
current study, we used dasatinib (BMS-324825), an FDA-
approved inhibitor of Bcr-Abl and Src family kinases, to suppress
the STAT5 pathway. Although a specific STAT5 inhibitor has not
yet been developed, lestaurtinib (CEP701), a new JAK2 inhibitor
that suppresses JAK2/STAT5 signaling is showing promise in
clinical trials for myeloproliferative disorders and pancreatic
cancer [33]. The recent emergence of clinically-tested inhibitors
for both NF-kB and STAT5 pathways makes them promising
candidates for targeted therapy of carboplatin-resistant tumors.
Additionally, a small molecule inhibitor for Bcl-2/Bcl-xL is also
available [18]. The capacity to target NF-kB, STAT5, and Bcl-2/
Bcl-xL pathways simultaneously, and thus maximize the suppres-
sion of Bcl-xL expression, should be of great benefit to ovarian
cancer patients who have developed carboplatin resistance.
In summary, we have compared the proteomes between
primary and recurrent ovarian tumor samples and have identified
several pro-inflammatory cytokines and nuclear proteins involved
in the inflammatory response pathway in recurrent tumors.
Among them, we found that preferential co-upregulation of NF-
kB and STAT5 represents an important mechanism in developing
carboplatin resistance in ovarian cancer. Furthermore, we showed
that Bcl-xL is the converging molecule of the two pathways, and
we provided evidence that one of the molecular mechanisms by
which NF-kB and STAT5 upregulation contributes to carboplatin
resistance is by preventing cell death through transcriptional
activation of Bcl-xL. The findings presented here provide evidence
of synergy between NF-kB and STAT5 in transcriptional
activation of Bcl-xL in ovarian cancer cells, and also indicate
potential molecular pathways to be targeted in order to enhance
chemotherapeutic effects. Further molecular studies and future
clinical trials using NF-kB and STAT5 inhibitors will address
clinical benefits of targeting Bcl-xL as an approach toward
enhancing the efficacy of chemotherapy in ovarian cancer
patients.
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